Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Filed with ASX · · 2 pages · English
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Firebrick Raises $1 million via Placement
- March 2023 Quarterly Activity Report & Appendix 4C
- Nasodine COVID-19 Trial Concludes Recruitment
- Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
- FRE files EU Paediatric Investigation Plan for Nasodine
Later from Firebrick Pharma
- June 2023 Quarterly Activity Report & Appendix 4C
- Firebrick Covid-19 Trial Achieves Primary Endpoint
- Firebrick Phase 3 Trial Closes with 500 Subjects
- Response to ASX Price and Volume Query
- Appendix 4E & Annual Report FY23
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma